An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

This research study is looking at a medicine called Trametinib. Trametinib is used alone or with another drug called dabrafenib to treat certain types of cancer, including melanoma (a type of skin cancer), lung cancer, a type of brain tumour called glioma, and thyroid cancer, especially when the cancer has a specific change (mutation) in something called the BRAF gene.

The main purpose of this study is to compare two different versions of Trametinib. One is the original drug, known as Mekinist, and the other is a new version being developed by another company. The researchers want to see if these two versions act the same way in the human body. This means checking if they are absorbed into the bloodstream at similar rates and reach similar levels. If they do, it tells us that the new version should be just as safe and effective as the original one for patients.

This is a 'bioequivalence' study, which is a common and important step when a new, often generic, version of a medicine is developed. It's like comparing two brands of a familiar product to make sure they do exactly the same job. By doing this, we can ensure that patients can potentially have access to more options for their treatment while maintaining high standards of safety and effectiveness.